Source Paper
Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease
Josep M. Canals, José R. Pineda, Jesús F. Torres-Peraza, Miquel Bosch, Raquel Martín-Ibañez et al.
Journal of Neuroscience • 2004
BDNF Administration Study
Objective: To test restoration of striatal enkephalinergic neuronal dysfunction through exogenous BDNF administration in a transgenic mouse model of Huntington's disease
This is a BDNF Administration Study protocol using mouse as the model organism. The procedure involves 4 procedural steps, 1 materials. Extracted from a 2004 paper published in Journal of Neuroscience.
Model and subjects
mouse • R6/1 transgenic mice crossed with bdnf +/- mice • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Generate double mutant mouse line • Assess motor dysfunction onset and severity • Administer exogenous BDNF
Primary readouts
- Onset of motor dysfunctions
- Severity of uncoordinated movements
- Loss of striatal dopamine
- Loss of cAMP-regulated phosphoprotein-32-positive projection neurons
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Generate double mutant mouse line
Cross-mate bdnf +/- mice with R6/1 transgenic mice to create transgenic mice with mutant Huntingtin and different levels of BDNF
Note: This creates a model to compare transgenic mice for mutant Huntingtin with different levels of BDNF
View evidence from paper
“we disrupted the expression of bdnf in a transgenic mouse model by cross-mating bdnf +/- mice with R6/1 mice”
Assess motor dysfunction onset and severity
Monitor and evaluate motor dysfunctions in the double mutant mice to determine if decreased BDNF levels advance the onset and increase severity of uncoordinated movements
Note: Behavioral pathology correlates with loss of striatal dopamine and cAMP-regulated phosphoprotein-32-positive projection neurons
View evidence from paper
“The decreased levels of this neurotrophin advance the onset of motor dysfunctions and produce more severe uncoordinated movements”
Administer exogenous BDNF
Administer exogenous BDNF to mice with insufficient endogenous BDNF levels to test restoration of striatal enkephalinergic neuronal dysfunction
Note: Route of administration, dosage, and frequency not specified in provided text
View evidence from paper
“This neuronal dysfunction can specifically be restored by administration of exogenous BDNF”
Evaluate neuronal degeneration patterns
Assess specific degeneration of enkephalinergic striatal projection neurons and loss of dopamine and cAMP-regulated phosphoprotein-32-positive projection neurons
Note: Enkephalinergic striatal projection neurons are the most affected cells in Huntington's disease
View evidence from paper
“the insufficient levels of BDNF cause specific degeneration of the enkephalinergic striatal projection neurons, which are the most affected cells in Huntington's disease”